Table 2.
Demographic and clinical characteristics of study subjects.
| Parameters | HealthCtl (n = 18) | HospCtl (n = 22) | CIS (n = 18) | RRMS (n = 16) | VI (n = 11) |
|---|---|---|---|---|---|
| Age: min–max (mean) | 23–58 (34.0) | 17–74 (43.1) | 20–64 (31.9) | 15–64 (35.6) | 19–86 (46.5) |
| Gender: % Female | 50 | 60 | 80 | 70 | 50 |
| 1 DMT (Yes: No) | N/A | N/A | 1*:17 | 1**:15 | N/A |
| 2 EDSS: min–max (mean) | N/A | N/A | 0.0–3.5 (1.7) | 1.0–7.5 (2.3) | N/A |
| 3 Stage (relapse: remission) | N/A | N/A | 1:16 (N/V = 1) | 16:0 | N/A |
| 4 Duration: min–max (mean) | N/A | N/A | N/A | 1–156 (34) | N/V |
1 DMT: disease-modifying therapy at the time of sample collection; 2 EDSS: Expanded Disability Status Scale score; 3 Disease stage at the time of sample collection; 4 Disease duration in months; N/A: not applicable; N/V: not available. * Fumarate. ** Natalizumab.